By Fineline Cube InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and mesutoclax (ICP-248) has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior line of therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | InnoCare Pharma Limited (HKG: 9969, SHA: 688428) |
| Product | Orelabrutinib + Mesutoclax (ICP-248) combination |
| Regulatory Status | Breakthrough Therapy Designation (BTD) from NMPA CDE |
| Indication | Marginal zone lymphoma (MZL) after ≥1 prior therapy |
| Announcement Date | 4 Aug 2026 |
Drug Profile & Mechanism of Action
- Orelabrutinib: Highly selective, novel BTK inhibitor independently developed by InnoCare that effectively avoids adverse reactions caused by off-target effects and significantly improves efficacy and safety
- Mesutoclax (ICP-248): Novel oral, highly selective BCL2 inhibitor independently developed by InnoCare that restores tumor cell apoptosis by selectively inhibiting the BCL2 protein, thereby suppressing tumor growth and proliferation
- Combination Rationale: Dual targeting of complementary pathways in MZL pathogenesis
Clinical Data Highlights
Previous clinical data have shown that the combination of orelabrutinib and mesutoclax demonstrated:
- Overall Response Rate (ORR): 100% in MZL patients who had received at least one prior line of therapy
- Safety Profile: Promising safety with manageable adverse events
- Patient Population: Relapsed/refractory MZL patients with limited treatment options
Strategic Significance
The Breakthrough Therapy Designation provides InnoCare Pharma with enhanced regulatory support and expedited review processes. This designation is reserved for drug candidates demonstrating substantial improvement over existing therapies for serious or life-threatening conditions.
Marginal zone lymphoma affects thousands of patients annually in China, with limited treatment options available for relapsed or refractory cases. The 100% ORR represents a potentially transformative improvement over current standard of care.
Market Opportunity & Competitive Landscape
- MZL Market: Significant unmet medical need in relapsed/refractory setting
- Competitive Positioning: First combination of selective BTK + BCL2 inhibitors for MZL in China
- Commercial Potential: BTD status may support priority review and premium pricing upon approval
- Global Strategy: Successful development could position InnoCare for international partnerships
Company Pipeline Strategy
“This breakthrough therapy designation represents a significant validation of our innovative approach to treating hematological malignancies,” said Dr. Jasmine Cui, Founder, Chairperson, and CEO of InnoCare Pharma. “The combination of our selective BTK inhibitor orelabrutinib with mesutoclax shows compelling clinical potential that could address critical unmet needs for MZL patients in China.”
InnoCare Pharma continues to advance multiple clinical programs across its pipeline, with particular focus on hematological malignancies and autoimmune disorders. The company maintains robust cash reserves to support ongoing development activities through anticipated regulatory milestones.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech